619 related articles for article (PubMed ID: 32224306)
1. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
6. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
[TBL] [Abstract][Full Text] [Related]
7. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
8. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ; López-Martin JA; Bendell J; Ott PA; Taylor M; Eder JP; Jäger D; Pietanza MC; Le DT; de Braud F; Morse MA; Ascierto PA; Horn L; Amin A; Pillai RN; Evans J; Chau I; Bono P; Atmaca A; Sharma P; Harbison CT; Lin CS; Christensen O; Calvo E
Lancet Oncol; 2016 Jul; 17(7):883-895. PubMed ID: 27269741
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
12. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
14. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Farago AF; Drapkin BJ; Lopez-Vilarino de Ramos JA; Galmarini CM; Núñez R; Kahatt C; Paz-Ares L
Future Oncol; 2019 Jan; 15(3):231-239. PubMed ID: 30362375
[TBL] [Abstract][Full Text] [Related]
15. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
17. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
18. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
19. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Leary A; Oaknin A; Trigo JM; Moreno V; Delord JP; Boni V; Braña I; Fernández C; Kahatt C; Nieto A; Cullell-Young M; Zeaiter A; Subbiah V
Eur J Cancer; 2023 Oct; 192():113259. PubMed ID: 37634282
[TBL] [Abstract][Full Text] [Related]
20. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Longo-Muñoz F; Castellano D; Alexandre J; Chawla SP; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Moreno V; Sanz-García E; Awada A; Santaballa A; Subbiah V
Eur J Cancer; 2022 Sep; 172():340-348. PubMed ID: 35830841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]